Results 101 to 110 of about 71,323 (284)
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle
ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley +1 more source
Three-dimensional echocardiographic analysis of electromechanical synchrony: comparison with three-dimensional and two-dimensional ejection fraction for evaluation of left ventricular systolic performance [PDF]
Einstein (São Paulo), 2008 Objective: To compare the three-dimensional echocardiographic analysisof left ventricular (LV) synchrony to LV ejection fraction (LVEF) as measuredby two-dimensional (2D) and three-dimensional (3D) echocardiography(ECHO).
Marcelo Luiz Campos Vieira +12 more
doaj
ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy +15 more
wiley +1 more source
Cardiovascular Ultrasound, 2009 Background Visual assessment of left ventricular ejection fraction (LVEF) is often used in clinical routine despite general recommendations to use quantitative biplane Simpsons (BPS) measurements.
Manouras Aristomenis +4 more
doaj +1 more source
Increased baseline ECG R-R dispersion predicts improvement in systolic function after atrial fibrillation ablation. [PDF]
, 2019 BackgroundAtrial fibrillation (AF) is associated with left ventricular (LV) systolic dysfunction which may improve after AF ablation. We hypothesised that increased ventricular irregularity, as measured by R-R dispersion on the baseline ECG, would ...
Buch, Eric +7 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk +12 more
wiley +1 more source
Peritoneal dialysis in older adults: evaluation of clinical, nutritional, metabolic outcomes, and quality of life [PDF]
, 2018 The number of older adults requiring dialysis is increasing worldwide, whereas the use of peritoneal dialysis (PD) in this population is lower respect to younger patients, despite the theoretical advantages of PD respect to hemodialysis.
Aceto, Paola +10 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li +12 more
wiley +1 more source
Novel echocardiographic techniques to assess left atrial size, anatomy and function
Cardiovascular Ultrasound, 2012 Three-dimensional echocardiography (3DE) and speckle tracking echocardiography (STE) have recently applied as imaging techniques to accurately evaluate left atrial (LA) size, anatomy and function.
Cameli Matteo +3 more
doaj +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source